The online version of this article (doi:10.1186/1475-2875-11-372) contains supplementary material, which is available to authorized users.
All authors declare that they have no competing financial interests.
All authors were present at the Scientific Forum. KV drafted the initial version of the manuscript. VM coordinated writing of the subsequent drafts of the manuscript. GB, VM and BA edited the second and final draft. All authors read and approved the final manuscript.
The World Health Organization (WHO) convened a malaria vaccines committee (MALVAC) scientific forum from 20 to 21 February 2012 in Geneva, Switzerland, to review the global malaria vaccine portfolio, to gain consensus on approaches to accelerate second-generation malaria vaccine development, and to discuss the need to update the vision and strategic goal of the Malaria Vaccine Technology Roadmap. This article summarizes the forum, which included reviews of leading Plasmodium falciparum vaccine candidates for pre-erythrocytic vaccines, blood-stage vaccines, and transmission-blocking vaccines. Other major topics included vaccine candidates against Plasmodium vivax, clinical trial site capacity development in Africa, trial design considerations for a second-generation malaria vaccine, adjuvant selection, and regulatory oversight functions including vaccine licensure.
Additional file 1: List of participants at the MALVAC Meeting: 20-21 February 2012. (DOCX 134 KB)12936_2012_2530_MOESM1_ESM.docx
Malaria Vaccine Technology Roadmap: http://www.malariavaccine.org/files/Malaria_Vaccine_TRM_Final.pdf.
World Health Organization: Most advanced malaria vaccine candidate and timing for policy recommendations. http://www.who.int/vaccine_research/diseases/malaria/vaccine_candidate_policy/en/index.html.,
malERA: A research agenda for malaria eradication. PLoS Med. 2011, 8 (1): 1-99.
Laurens MB, Roestenberg M, Moorthy VS, The Consensus Group on Design of Clinical Trials of Controlled Human Malaria Infection: A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines. Vaccine. 2012, 30 (36): 5302-5304. 10.1016/j.vaccine.2012.04.088. CrossRefPubMed
World Health Organization: NIAID/WHO Workshop on Heterologous Prime-Boost Strategies for HIV, Malaria and Tuberculosis Vaccines. http://www.who.int/vaccine_research/diseases/malaria/niaid_workshop_hiv_malaria_tb_2012/en/index.html.
Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, Rare L, Baisor M, Lorry K, Brown GV, Pye D, Irving DO, Smith TA, Beck HP, Alpers MP: A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis. 2002, 185: 820-827. 10.1086/339342. CrossRefPubMed
malERA Consultative Group on Vaccines: A research agenda for malaria eradication: vaccines. PLoS Med. 2011, 8: 24-33. CrossRef
U.S Department of Health and Human Services Food and Drug Administration: Vaccines and Related Biological Products Advisory Committee Meeting, May 27, 1998 (transcript). http://www.fda.gov/ohrms/dockets/ac/98/transcpt/3422t2a.pdf.
U.S. Department of Health and Human Services Food and Drug Administration: 21 CFR Parts 314 and 601. Fed Regist. 2002, 67 (105): 37988-37998.
- MALVAC 2012 scientific forum: accelerating development of second-generation malaria vaccines
Kirsten S Vannice
Graham V Brown
Bartholomew D Akanmori
Vasee S Moorthy
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II